Log In
Print
BCIQ
Print
Print this Print this
 

ISIS-HBVRx (formerly ISIS-GSK3Rx)

  Manage Alerts
Collapse Summary General Information
Company Isis Pharmaceuticals Inc.
DescriptionAntisense oligonucleotide targeting HBV RNA
Molecular Target
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat HBV infection; Treat viral infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

$35.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today